loading
Precedente Chiudi:
$1.25
Aprire:
$1.26
Volume 24 ore:
981.47K
Relative Volume:
0.55
Capitalizzazione di mercato:
$142.11M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.7515
EPS:
-1.65
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
+9.73%
1M Prestazione:
+6.90%
6M Prestazione:
-6.77%
1 anno Prestazione:
-77.04%
Intervallo 1D:
Value
$1.19
$1.27
Intervallo di 1 settimana:
Value
$1.12
$1.30
Portata 52W:
Value
$0.6611
$5.92

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
Nome
Fate Therapeutics Inc
Name
Telefono
858.875.1803
Name
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
Dipendente
181
Name
Cinguettio
@fatethx
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
FATE's Discussions on Twitter

Confronta FATE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.24 143.29M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-18 Aggiornamento BofA Securities Underperform → Neutral
2024-06-17 Aggiornamento Piper Sandler Neutral → Overweight
2023-03-27 Ripresa Wells Fargo Equal Weight
2023-01-24 Downgrade H.C. Wainwright Buy → Neutral
2023-01-06 Downgrade BMO Capital Markets Outperform → Market Perform
2023-01-06 Downgrade BofA Securities Buy → Underperform
2023-01-06 Downgrade Cowen Outperform → Market Perform
2023-01-06 Downgrade Piper Sandler Overweight → Neutral
2023-01-06 Downgrade Stifel Buy → Hold
2023-01-06 Downgrade Truist Buy → Hold
2023-01-06 Downgrade Wedbush Outperform → Neutral
2023-01-03 Downgrade Guggenheim Buy → Neutral
2022-12-22 Downgrade Oppenheimer Outperform → Perform
2022-12-15 Iniziato Goldman Sell
2022-11-04 Ripresa Cantor Fitzgerald Overweight
2022-10-10 Iniziato Canaccord Genuity Buy
2022-08-18 Ripresa Wells Fargo Overweight
2022-07-28 Iniziato Needham Hold
2022-07-11 Aggiornamento BMO Capital Markets Market Perform → Outperform
2022-06-03 Iniziato Robert W. Baird Neutral
2022-02-11 Ripresa BMO Capital Markets Market Perform
2021-12-15 Aggiornamento Wedbush Neutral → Outperform
2021-12-07 Iniziato Cowen Outperform
2021-11-09 Aggiornamento Citigroup Neutral → Buy
2021-08-26 Iniziato Morgan Stanley Equal-Weight
2021-06-07 Aggiornamento H.C. Wainwright Neutral → Buy
2021-05-07 Aggiornamento Wedbush Neutral → Outperform
2021-04-26 Ripresa Jefferies Buy
2021-02-26 Iniziato BofA Securities Buy
2021-02-26 Downgrade Wedbush Outperform → Neutral
2021-02-11 Downgrade Citigroup Buy → Neutral
2021-01-27 Ripresa H.C. Wainwright Neutral
2020-05-13 Iniziato H.C. Wainwright Buy
2020-03-04 Iniziato Barclays Overweight
2020-01-09 Downgrade BMO Capital Markets Outperform → Market Perform
2019-12-30 Reiterato Mizuho Buy
2019-12-09 Aggiornamento Wells Fargo Market Perform → Outperform
2019-11-12 Iniziato SunTrust Buy
2019-11-06 Downgrade Wells Fargo Outperform → Market Perform
2019-10-01 Iniziato Stifel Buy
2019-08-09 Iniziato BTIG Research Buy
2019-07-22 Iniziato Cantor Fitzgerald Overweight
2019-07-12 Iniziato Oppenheimer Outperform
2019-06-13 Iniziato Mizuho Buy
2019-06-07 Iniziato ROTH Capital Neutral
2019-05-31 Iniziato Guggenheim Buy
2019-05-24 Ripresa Citigroup Buy
2019-03-28 Iniziato SVB Leerink Outperform
2019-01-03 Downgrade Stephens Overweight → Equal-Weight
2018-11-05 Iniziato Jefferies Buy
2018-08-01 Iniziato Citigroup Buy
2018-03-06 Downgrade H.C. Wainwright Buy → Neutral
Mostra tutto

Fate Therapeutics Inc Borsa (FATE) Ultime notizie

pulisher
Jul 25, 2025

What drives Fate Therapeutics Inc. stock priceFree Market Dynamics Reports - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

How Fate Therapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - Newser

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Fate Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Is Fate Therapeutics Inc. a good long term investmentExceptional gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Fate Therapeutics Inc. Stock Analysis and ForecastLightning-fast capital gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 18, 2025

why fate therapeutics inc. stock attracts strong analyst attentionFree Day Trading Recommendations - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

what makes fate therapeutics inc. stock price move sharplyIntraday Trade Ideas - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of “Hold” from Brokerages - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Fate Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully - Yahoo Finance

Jul 14, 2025
pulisher
Jul 11, 2025

10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey

Jul 11, 2025
pulisher
Jul 08, 2025

Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth (ADIA, FATE, MESO, CRSP) - FinancialContent

Jul 08, 2025
pulisher
Jul 05, 2025

Research Analysts Offer Predictions for FATE Q2 Earnings - Defense World

Jul 05, 2025
pulisher
Jul 03, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 03, 2025
pulisher
Jul 03, 2025

Fate Therapeutics shares rise 3.57% after-hours after granting non-qualified stock options to a new employee. - AInvest

Jul 03, 2025
pulisher
Jul 02, 2025

H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $5 - Investing.com

Jul 02, 2025
pulisher
Jun 30, 2025

Fate Therapeutics, Inc.(NasdaqGM: FATE) added to Russell Microcap Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

Fate Therapeutics (NASDAQ:FATE) Downgraded to “Sell” Rating by Wall Street Zen - Defense World

Jun 28, 2025
pulisher
Jun 15, 2025

Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st

Jun 15, 2025
pulisher
Jun 14, 2025

Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada

Jun 11, 2025

Fate Therapeutics Inc Azioni (FATE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):